Telix Pharmaceuticals shares (ASX: TLX) climbed 2.75% on Wednesday to close at A$15.69, boosted by the completion of patient enrollment in the pivotal Phase 3 BiPASS prostate cancer imaging study. The milestone, layered on top of a strong second-quarter revenue performance and a new strategic partnership with Regeneron, has kept sentiment skewed toward the bulls even as regulatory and execution risks remain part of the conversation.
The 2.75% gain on the day took the Telix share price to A$15.69, up 38.12% YTD, and back above its 30-day simple moving average at A$15.63 (a level technical traders often read as a sign that short-term momentum has turned constructive). The bounce extends a positive pattern that began after the company’s Q2 2026 revenue update, when shares rose as markets digested better-than-expected numbers and upbeat full-year guidance.
Driving Telix Pharma Shares
BiPASS was the centerpiece of Wednesday’s news, as Telix finished enrolling 350 men across the United States and Australia in the Phase 3 study, which evaluates the company’s Illuccix and Gozellix (68Ga-PSMA-PET) imaging agents combined with MRI in the pre-biopsy setting for suspected prostate cancer.
It is the first registrational study of a 68Ga-PSMA-PET agent in this diagnostic role, testing whether combining PSMA-PET/CT with MRI can improve detection of clinically significant prostate cancer, reduce unnecessary biopsies, and better target biopsies compared with current standard practice. Telix has also reached alignment with the U.S. FDA on an NDA pathway for BiPASS that, if approved, would support reimbursement as a new product and broaden access to PSMA-PET imaging to a substantially larger patient population. The program builds on the earlier PRIMARY and PRIMARY2 studies, which showed that adding PSMA-PET to MRI can halve the number of biopsies without missing clinically significant disease.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Fundamental Support
The financial backbone behind the story is equally notable. Telix reported Q2 2026 group revenue of US$247 million, up 7% quarter-on-quarter and 21% year-on-year, with Precision Medicine revenue of US$202 million growing 9% sequentially and 30% annually.
For FY 2026, the company now expects revenue and other income to exceed US$1 billion, with revenue tracking toward the upper end of prior guidance of US$950–970 million plus US$40 million in non-refundable income from its Regeneron collaboration. Unaudited first-half revenue of US$477 million was driven by robust demand for Illuccix and the successful launch of Gozellix.
That trajectory has allowed Telix to update FY26 R&D expenditure guidance to US$230–270 million while still funding multiple late-stage programs, underscoring the cash-generative nature of the commercial PSMA imaging platform.
On the partnership front, Telix has entered a strategic collaboration with Regeneron to jointly develop and commercialize next-generation radiopharmaceutical therapies, initially focused on lung cancer. Regeneron provided a non-refundable US$40 million payment that contributes to FY26 other income, giving Telix both capital and external validation of its radiopharma platform.
Pipeline
Beyond BiPASS, the late-stage pipeline is broadening. Telix has secured FDA alignment to move the ProstACT Global Phase 3 study of TLX591-Tx for metastatic castration-resistant prostate cancer into Part 2, and has dosed the first patient in the Phase 3 LUTEON trial of TLX250-Tx for renal cancer. In Japan, enrollment is complete in a Phase 3 registrational study of TLX591-Px (Illuccix), with an NDA submission in preparation and a conditional approval application under review that could expedite the process if granted. The company has also recently received European acceptance for a brain cancer imaging drug, extending its diagnostic reach into CNS indications.
What Next?
On the analyst front, Jefferies has pointed to meaningful upside tied to potential product approvals, citing the late-stage pipeline and growing commercial base. RBC, however, recently downgraded the stock to Sector Perform from Outperform while maintaining an A$18 price target, suggesting at least one major broker believes a good portion of near-term upside is already priced in.
From a technical standpoint, reclaiming the 30-day moving average puts momentum back in the bulls’ hands, but with the stock up over 38% this year, positioning is increasingly crowded heading into key catalysts. Telix holders are now set with evaluating genuine operational progress and elevated expectations on one side, and a demanding valuation plus lingering regulatory scars on the other.
